Navigation Links
Cholesterol-lowering drugs and the effect on muscle repair and regeneration
Date:9/24/2008

HILTON HEAD, SCStatins are powerful drugs that reduce "bad" cholesterol and thus cut the risk of a heart attack. While these medications offer tremendous benefits to millions, they can carry side effects for some. The most frequently reported consequence is fatigue, and about nine percent of patients report statin-related pain. Both can be exacerbated when statin doses are increased, or physical activity is added. The results of a new study may offer another note of caution for high-dose statin patients. Working with primary human satellite cell cultures, researchers have found that statins at higher doses may affect the ability of the skeletal muscleswhich allow the body to moveto repair and regenerate themselves.

The study is entitled "Simvastatin Reduces Human Primary Satellite Cell Proliferation in Culture." It was conducted by Anna Thalacker-Mercer, Melissa Baker, Chris Calderon and Marcas Bamman, University of Alabama at Birmingham. They will discuss their findings at the American Physiological Society (APS; www.The-APS.org) conference, The Integrative Biology of Exercise V. The meeting is being held September 24-27, 2008 in Hilton Head, SC.

The Study

Statins have been reported to have adverse effects on skeletal muscle in both human and animal models causing cramping and fatigue and potentially myopathy. Relatively little is known regarding the effect of statins on the muscle progenitor cells (i.e., satellite cells (SC)) which play a key role in skeletal muscle repair and regeneration following exercise or injury. SC remain in a quiescent state until stimulated to proliferate. Statins are known to have antiproliferative effects in other cell types and therefore may inhibit or effect this critical step in muscle repair. Thus it is important to understand the influence of statins on SC function which may further affect the overall health and physiology of human skeletal muscle..

The study examined the proliferative capacity of human satellite cells in culture, which were exposed, to a lipophilic statin: simvastatin. The aim of the study was to determine SC viability during proliferation when treated with statins which may be indicative of the ability of SCs to undergo mitosis (i.e. divide to make new cells).

The research team used primary cell lines isolated from quadriceps muscle biopsies. SC were mixed and grown for 48 hours with several concentrations of statin: 0.0, 0 plus the solvent DMSO (control), 0.05, 0.1, 1.0, 10, or 100M. The MTS assay was utilized to measure cell viability/reproducibility.

Additionally the investigators determined the effects of varying concentrations of simvastatin on SCs in different states (i.e., undergoing differentiation or differentiated into myotubes).

Key Findings

The researchers found the following:

  • There was a dose dependent decrease in the viability of the satellite cells at 1.0, 10 and 100M concentrations of simvastatin. At approximately 5.0 M concentration the viability of the proliferating cells was reduced by 50% (equivalent to the availability of simvastatin in circulation from a 40 milligram dose per day used in some patients). Specifically, the higher end concentrations led to reduced SC proliferation, which would likely negatively affect the muscle's ability to heal and/or repair itself.

  • There was no change in the viability of satellite cells at concentrations of 0.05 or 0.1M.

  • Cell viability was reduced by approximately half in differentiating cells and myotubes with concentrations of 1.0 and 5.0 M, respectively.

Next Steps

According to Dr. Thalacker-Mercer, a member of the research team, "While these are preliminary data and more research is necessary, the results indicate serious adverse effects of statins that may alter the ability of skeletal muscle to repair and regenerate due to the anti-proliferative effects of statins."

Looking ahead, she added, "We are very interested in these effects in the older population. It is possible that older adults may not be able to distinguish between muscle pain related to a statin effect or an effect of aging and therefore adverse effects of statins in older adults may be under-reported. Therefore, our next step is to examine statins among older adults."


'/>"/>

Contact: Donna Krupa
DKrupa@the-aps.org
703-967-2751
American Physiological Society
Source:Eurekalert

Related biology news :

1. Research exposes new target for malaria drugs
2. NIST trumps the clumps: Making biologic drugs safer
3. Indiana U scientists uncover potential key to better drugs to fight toxoplasmosis parasite
4. Test of bacteria toxin delivery system could pave way for new antibiotic drugs
5. Compound has potential for new class of AIDS drugs
6. UF scientists discover compound that could lead to new blood pressure drugs
7. USC School of Dentistry researchers uncover link between osteoporosis drugs and jaw infection
8. Your babys brain on drugs (and alcohol and tobacco)
9. Prednisone tablets less variable than marketed drugs
10. Ant guts could pave the way for better drugs
11. Simplifying manufacture of drugs, plastics earns UH chemist top honor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 Report ... ... and should reach $11.4 billion by 2021, growing at a ... Report Includes - An overview of the global markets for ... from 2015, estimates for 2016, and projections of compound annual ...
(Date:2/7/2017)... LONG BEACH, New York , February 7, 2017 ... formerly known as ID Global Solutions Corporation [OTC: IDGS], ... identification, identity management and electronic transaction processing services, is ... a reorganization of the Company. Effective January ... Chairman of the Board of Directors, CEO and President. ...
(Date:2/2/2017)... 2017  EyeLock LLC, a market leader of iris-based ... " What You Should Know About Biometrics in the ... authenticity is a growing concern. In traditional schemes, cryptography ... traditional authentication schemes such as username/password suffer from inherent ... offers an elegant solution to the problem of high-security ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... ... February 23, 2017 , ... BellBrook Labs is ... include an array of biochemical analyses critical for Lead Discovery. The company’s ... and SAR programs, including inhibitor potency and selectivity, mechanism of action, and inhibitor ...
(Date:2/23/2017)... ROCHESTER, Minn. , Feb. 23, 2017 /PRNewswire/ ... a new product line of oncolytic vaccinia viruses ... Genelux Corporation as part of Genelux,s proprietary, vaccinia ... "We are excited to enter into a partnership ... time, selected oncolytic vaccinia viruses for use in ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Greater Gift Initiative, ... partnership with Compass Research . GGI's mission is to advance global health and ... child in need in honor of each clinical trial volunteer. The vision of GGI ...
(Date:2/22/2017)... 22, 2017  Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet ... innovative biopharmaceutical products for companion animals, will host a live ... ET to discuss financial results from the fourth quarter and ... participants and investors may access the audio webcast ... ...
Breaking Biology Technology: